255 related articles for article (PubMed ID: 17493241)
21. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Kommoss S; du Bois A; Ridder R; Trunk MJ; Schmidt D; Pfisterer J; Kommoss F;
Br J Cancer; 2007 Jan; 96(2):306-13. PubMed ID: 17242700
[TBL] [Abstract][Full Text] [Related]
22. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
24. High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman.
Quddus MR; Rashid LB; Hansen K; Sung CJ; Lawrence WD
Histopathology; 2009 May; 54(6):771-3. PubMed ID: 19438755
[No Abstract] [Full Text] [Related]
25. [Low grade malignant ovarian carcinomas. A retrospective study of 132 cases].
Randrianjafisamindrakotroka NS; Hedelin G; Philippe E; Schaffer P
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(7):761-7. PubMed ID: 1469230
[TBL] [Abstract][Full Text] [Related]
26. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
27. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
28. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
29. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
Köbel M; Huntsman D; Gilks CB
Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
[TBL] [Abstract][Full Text] [Related]
30. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
[TBL] [Abstract][Full Text] [Related]
31. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
33. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Brustmann H
Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
[TBL] [Abstract][Full Text] [Related]
35. Stromal p16 expression is significantly increased in malignant ovarian neoplasms.
Yoon N; Yoon G; Park CK; Kim HS
Oncotarget; 2016 Oct; 7(40):64665-64673. PubMed ID: 27572321
[TBL] [Abstract][Full Text] [Related]
36. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma.
Khouja MH; Baekelandt M; Nesland JM; Holm R
Int J Gynecol Pathol; 2007 Oct; 26(4):418-25. PubMed ID: 17885492
[TBL] [Abstract][Full Text] [Related]
37. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms.
Ohishi Y; Oda Y; Kurihara S; Kaku T; Yasunaga M; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Aug; 40(8):1168-75. PubMed ID: 19368953
[TBL] [Abstract][Full Text] [Related]
38. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
39. Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma.
Muirhead DM; Hoffman HT; Robinson RA
J Clin Pathol; 2006 Jul; 59(7):711-5. PubMed ID: 16467168
[TBL] [Abstract][Full Text] [Related]
40. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]